Oncology Urology Unit, Department of Urology, Fundació Puigvert, Universitat Autònoma de Barcelona, Carrer de Cartagena 340-350, 08025, Barcelona, Spain.
Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Urology, Department of Clinical Sciences and Community Health, University of Milan, Via della Commenda, 10, 20122, Milan, Italy.
Eur J Surg Oncol. 2020 Nov;46(11):1989-1997. doi: 10.1016/j.ejso.2020.06.024. Epub 2020 Jul 4.
To assess the accuracy of ureteroscopic (URS) biopsies in predicting stage and grade at final pathology in upper tract urothelial carcinoma (UTUC).
The meta-analysis was performed in accordance with the PRISMA statement. Studies providing data on tumor stage and grade at URS biopsy and surgical specimens were included. The negative predictive value (NPV) implies concordance between the absence of subepithelial connective tissue invasion or the presence of low-grade tumors at URS biopsy and the absence of a muscle-invasive disease in the final pathology.
A total of 23 studies were included (3547 patients). The stage-to-stage match between URS biopsy/final pathology showed a positive predictive value (PPV) for cT1+/muscle-invasive disease of 94% (95% CI: 84%-100%) and a NPV for cTa-Tis/non-muscle-invasive disease of 60% (95% CI: 52%-68%). The grade-to-grade match between URS biopsy/final pathology was 66% (95% CI: 55%-77%) for low-grade (cLG/pLG) tumors and 97% (95% CI: 94%-98%) for high-grade (cHG/pHG) tumors. The PPV for cHG/muscle-invasive disease was 60% (95% CI: 54%-66%) and the NPV for cLG/non-muscle-invasive disease was 77% (95% CI: 73%-82%). The undergrading and understaging rates were 32% (95%CI: 25%-38%) and 46% (95% CI: 38%-54%), respectively.
There is a substantial correlation between tumor grade at URS biopsy and the final pathology. The identification of cHG tumors and subepithelial connective tissue invasion (cT1+) in URS biopsy showed a moderate and a strong correlation with invasive UTUC, respectively. Nevertheless, a certain risk of undergrading and understaging should be assumed.
评估输尿管镜活检术(URS)在预测上尿路上皮癌(UTUC)最终病理分期和分级中的准确性。
本 meta 分析按照 PRISMA 声明进行。纳入提供 URS 活检和手术标本肿瘤分期和分级数据的研究。阴性预测值(NPV)表示 URS 活检中无黏膜下结缔组织浸润或低级别肿瘤与最终病理中无肌层浸润性疾病之间的一致性。
共纳入 23 项研究(3547 例患者)。URS 活检/最终病理分期之间的分期匹配显示,cT1+/肌层浸润性疾病的阳性预测值(PPV)为 94%(95%CI:84%-100%),cTa-Tis/非肌层浸润性疾病的 NPV 为 60%(95%CI:52%-68%)。URS 活检/最终病理分级匹配方面,低级别(cLG/pLG)肿瘤为 66%(95%CI:55%-77%),高级别(cHG/pHG)肿瘤为 97%(95%CI:94%-98%)。cHG/肌层浸润性疾病的 PPV 为 60%(95%CI:54%-66%),cLG/非肌层浸润性疾病的 NPV 为 77%(95%CI:73%-82%)。低估和分期不当的发生率分别为 32%(95%CI:25%-38%)和 46%(95%CI:38%-54%)。
URS 活检肿瘤分级与最终病理之间存在显著相关性。URS 活检中 cHG 肿瘤和黏膜下结缔组织浸润(cT1+)的识别与浸润性 UTUC 具有中等和较强的相关性。然而,应该假设存在一定的低估和分期不当的风险。